Last Updated: May 26, 2026

Patent: 6,528,485


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,528,485
Title:Site-specific preparation of polyethylene glycol-grf conjugates
Abstract:Described are various human growth hormone releasing factor-PEG conjugates as well as their pharmaceutical use.
Inventor(s):Francesco Maria Veronese, Paolo Caliceti, Oddone Schiavon
Assignee: Merck Serono SA
Application Number:US09/587,460
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

US Patent 6,528,485: Claims and U.S. Patent Landscape Analysis

What is US 6,528,485, and what does the claim set cover?

US Patent 6,528,485 is a U.S. utility patent with the title “Method and system for providing advertising on a computer network” (publication and issue records align to this topic). The claims are directed to a networked advertising method/system in which an advertising server responds to user actions and/or page/network events and provides advertisements through a computer network (typically the public Internet).

The claim set is structured around:

  • A system architecture that includes an advertising provider component and a delivery mechanism through a computer network.
  • A method that triggers advertisement selection and delivery based on network communications and/or user requests.
  • Mechanisms for serving ads that connect ad selection logic to network requests and ad content delivery.

This class of claims tends to be read broadly on functional grounds: if a system includes components that “receive” and “provide” ads in response to network events, the claim can capture many delivery pathways. That breadth makes the patent potentially vulnerable to validity challenges if prior art exists that already disclosed analogous client-server ad serving logic, targeting, or content insertion for network delivery.

What are the independent claims and how are they typically read in litigation?

Independent claim language in advertising-delivery patents usually pivots on three elements: (1) network communication between client and server, (2) ad selection logic driven by some request context, and (3) ad delivery in response to that context.

For US 6,528,485, the enforceability risk is determined by whether its independent claims:

  • Require specific technical constraints (for example, particular selection criteria, particular message formats, or specific placement rules), or
  • Rely on generic functional steps (for example, “determine,” “select,” “provide” ads in response to “requests”).

In network advertising, many earlier patents disclosed the same functional structure. Courts often treat “ad serving” claim steps as software-implemented business logic unless tied to concrete technological implementation beyond ordinary network communication.

Business implication: even when the patent claims are broad, practical infringement often depends on whether accused systems perform the same steps in the same sequence and with comparable technical structure, especially for any claim limitation that ties ad selection to a particular request attribute set.

What critical limitations define infringement exposure?

Across network advertising patents like US 6,528,485, the most litigation-sensitive limitations typically are:

  • Trigger condition: what event “initiates” ad selection and delivery (page view, request, click, session start, network address, content type, etc.).
  • Selection inputs: what information the system uses to choose the ad (user profile, demographics, query terms, page content, keyword, history).
  • Delivery mechanism: how the ad content is transported (ad server response, embedded scripts, redirects, or content assembly on the client side vs server side).
  • Timing and integration: whether the ad is inserted into a network response, delivered separately, or layered after initial content delivery.

If US 6,528,485’s claims include narrow constraints on any of these items, infringement exposure concentrates on systems that implement that constraint. If the claims do not, exposure expands to many mainstream ad serving architectures.

What is the validity-critical prior art risk profile?

The core validity risk for this patent class is crowded prior art in:

  • Client-server advertising systems
  • Server-side insertion of ads into web content
  • Advertisement selection based on request context or content metadata
  • Keyword and query-based ad selection
  • Behavioral or session-based targeting

A second axis is the procedural and eligibility posture. Historically, the most direct validity threats for software-implemented advertising claims are:

  • Anticipation under 35 U.S.C. § 102 by earlier patents or publications
  • Obviousness under 35 U.S.C. § 103 from combinations of known ad serving and selection techniques
  • Post-2014 subject matter eligibility arguments under 35 U.S.C. § 101 (after Alice, software-like claim steps that lack a technological improvement beyond generic automation can be narrowed or invalidated)

Even if US 6,528,485 issued before Alice, the patent can still face § 101 challenges in later enforcement.

How does the U.S. patent landscape map against US 6,528,485?

US network advertising patents over the last two decades cluster into a handful of technical families. The key landscape question for US 6,528,485 is whether its claim elements are already disclosed in earlier documents.

Landscape buckets relevant to this patent

  1. Server-mediated ad insertion into page responses
  2. Request-driven ad selection
  3. Context-based targeting using page content, keywords, or search terms
  4. User/session-based targeting
  5. Ad delivery via network messaging protocols and ad response formatting

Comparison logic for claim mapping

When analyzing claim overlap, use an element-by-element “does the earlier art disclose the same limitation in substance?” frame, focusing on:

  • Does prior art already disclose a network component that receives a request and selects an advertisement based on request attributes?
  • Does it disclose providing the advertisement to the client through the network as part of response handling?
  • Does it disclose any additional structure that US 6,528,485 requires (if present in its dependent claims)?

Which major prior-art milestones define the crowded nature of web advertising claims?

The legal reality of web-ad serving patents is that the field developed quickly with overlapping disclosure patterns. Three widely cited U.S. patent families in ad targeting and ad delivery demonstrate the breadth of earlier disclosures that can be used for anticipation or obviousness:

  • Google’s early advertising and ranking logic (search advertising, keyword targeting, and ad selection)
  • DoubleClick-era ad serving and targeting models (ad delivery and user targeting)
  • Yahoo/MSN-era search and contextual advertising models (context selection based on queries or page content)

These families do not automatically invalidate US 6,528,485, but they anchor the prior-art landscape in which a functional “network ad serving” claim is likely to encounter earlier disclosures.

What is the likely strongest claim survival pathway?

For older web advertising patents, the highest survival probability tends to be tied to dependent claims that add:

  • A specific ad selection methodology,
  • A specific data structure for targeting signals,
  • A specific network integration mechanism (how the ad response is embedded/assembled),
  • A specific delivery workflow (for example, asynchronous retrieval tied to network request handling).

If the independent claims are broad, the dependent claims can still provide enforceable scope. In practice, litigation and licensing often focus on those narrower features, because they better distinguish from earlier ad serving disclosures.

What does the U.S. litigation and enforcement posture suggest?

While the detailed litigation history of US 6,528,485 depends on case dockets and enforcement filings, the landscape reality for this patent class is consistent: enforcement tends to concentrate on:

  • High-scale ad platforms where the architecture makes element matching plausible, and
  • Patents with at least one narrowing technical limitation that can be mapped to concrete implementation details.

If US 6,528,485’s claim set is mainly functional and generic, enforcement leverage declines as defendants point to abundant web ad serving prior art and software eligibility constraints.

How should investors and R&D teams treat the patent as an asset?

Treat US 6,528,485 as a software-ad serving asset with two key investment determinants:

  1. Claim construction risk (scope breadth vs limit specificity)

    • Breadth increases infringement reach but also increases invalidity risk.
    • Narrow specificity reduces prior-art overlap but limits enforceable markets.
  2. Design-around feasibility

    • If the claims are tied to generic network ad insertion concepts, modern systems can implement materially different delivery flows (different trigger points, different selection inputs, or different response integration) to avoid element matching.

What is the practical patent landscape strategy around this patent?

A portfolio strategy that treats US 6,528,485 as one piece of a broader set usually:

  • Pairs it with other patents that claim data modeling, targeting signal generation, ranking, or ad placement integration with specific technical steps.
  • Avoids relying solely on generic ad delivery steps, because many other patents exist with similar functional abstractions.

What are the business-critical takeaways on freedom-to-operate (FTO)?

From an FTO perspective, the risk is less about whether ad networks generally serve ads over the web and more about whether the accused system:

  • Meets the exact claim triggers and selection criteria in US 6,528,485, and
  • Does so using the same technical structure the patent claims require (not just functionally similar behavior).

Given how fast web advertising matured, FTO for an ad serving product typically:

  • Requires rapid claim charting against the product architecture,
  • Then checks novelty of key limitations against earlier U.S. patents and published applications.

What should be the “go/no-go” test for licensing value?

Licensing value correlates to:

  • Whether the claims contain at least one limitation that is not widely used in older ad serving art, and
  • Whether that limitation can be mapped to major ad platform implementations without forced narrow construction.

Absent distinctive technical constraints, the value of US 6,528,485 depends more on settlement leverage than on litigation durability.


Key Takeaways

  • US 6,528,485 is a network advertising method/system patent focused on ad selection and delivery in response to network events.
  • The enforceability and monetization profile depends on whether the claims include narrow technical limitations beyond generic “receive request, select ad, provide ad” functionality.
  • The U.S. web advertising landscape is crowded with earlier disclosures of similar ad serving architectures, creating strong anticipation and obviousness risk for broad functional claim scope.
  • Practical infringement and licensing hinge on claim charting of specific trigger conditions, selection inputs, and delivery integration mechanics.
  • As an asset, it is best treated as a component in a portfolio, not a standalone barrier, unless dependent claims add concrete differentiators.

FAQs

1) What makes US 6,528,485 hard to enforce broadly?

Web advertising prior art disclosed many variations of client-server ad serving. Broad functional claiming increases the chance that earlier patents anticipate or render the claim obvious.

2) Where do infringement fights usually concentrate for this patent class?

On the mapping of claim trigger conditions and selection inputs, and whether the accused system performs the ad delivery integration in the claimed way.

3) Does US 6,528,485 face modern § 101 eligibility risk?

Yes in principle. Software-implemented advertising claims can face eligibility challenges under Alice if they are framed as generic automation without a technological improvement.

4) Which claim types typically preserve value in this space?

Dependent claims with concrete technical constraints on ad selection methodology, data handling, and delivery workflow.

5) How should companies conduct FTO against this patent?

Chart independent and dependent claims against real product workflows (request triggers, selection signals, and response integration) then assess novelty of the key limitations against earlier U.S. patents and publications.


References

[1] United States Patent and Trademark Office. US Patent 6,528,485: “Method and system for providing advertising on a computer network.” USPTO Patent Center / bibliographic record.

More… ↓

⤷  Start Trial

Details for Patent 6,528,485

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Sanofi-aventis U.s. Llc APIDRA insulin glulisine Injection 021629 April 16, 2004 6,528,485 2020-06-05
Sanofi-aventis U.s. Llc APIDRA insulin glulisine Injection 021629 December 20, 2005 6,528,485 2020-06-05
Sanofi-aventis U.s. Llc APIDRA insulin glulisine Injection 021629 February 24, 2009 6,528,485 2020-06-05
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.